Eli Lilly's Alzheimer's Drug Shows Promise in Slowing Cognitive Decline.

Eli Lilly's clinical trial of an experimental Alzheimer's drug, donanemab, showed it can slow the progress of the disease and allow patients to have longer periods of independent living. The drug is not a cure and comes with significant side effects, including a risk of brain swelling that can result in death. However, the results may be a turning point in the long and frustrating quest to find an Alzheimer's treatment. The drug attacks amyloid, bolstering the hypothesis that the disease is driven by hard, Brillo-like plaques in the brain made of amyloid protein.